REG - Abingdon Health PLC - Total Voting Rights – 31 May 2024

Abingdon HealthAnnouncement

31/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe5006Qa&default-theme=true

RNS Number : 5006Q  Abingdon Health PLC  31 May 2024

31 May 2024

Abingdon Health Plc

("AH", the "Company" or the "Group")

Total Voting Rights - 31 May 2024

For the purposes of the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules ("DTRs"), the Company's issued share capital as at 31 May
2024 consisted of 126,716,822 ordinary shares of 0.025 pence each in the
Company ("Ordinary Shares"), and 182,316,812 Deferred Shares. The Deferred
Shares do not confer any voting rights. The Company does not hold any shares
in Treasury. Therefore, the total number of voting rights in the Company was
126,716,822.

 

The above figure of 126,716,822 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the DTRs.

For further information, please contact:

 Abingdon Health Plc                                     www.abingdonhealth.com/investors

 Chris Yates, Chief Executive Officer

 Chris Hand, Non-Executive Chairman
 WH Ireland Limited (Sole Broker and Nominated Advisor)  Tel: +44 (0)20 7220 1666

 Chris Fielding / Isaac Hooper (Corporate Finance)

 Fred Marshall (Corporate Broking)

 

The person responsible for arranging the release of this announcement on
behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

 

About Abingdon Health plc

 

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success".

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations; and produces lateral flow tests
in areas such as infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making and targeted intervention; and can support
better outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com/)  e-commerce site offers consumers a
range of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRQKKBKBBKDDPN